Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
McKesson
Boehringer Ingelheim
Medtronic

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Duvelisib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for duvelisib and what is the scope of freedom to operate?

Duvelisib is the generic ingredient in one branded drug marketed by Verastem Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Duvelisib has one hundred and thirty patent family members in thirty countries.

One supplier is listed for this compound.

Summary for duvelisib
International Patents:130
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 55
Clinical Trials: 22
Patent Applications: 146
Drug Prices: Drug price trends for duvelisib
DailyMed Link:duvelisib at DailyMed
Drug Prices for duvelisib

See drug prices for duvelisib

Recent Clinical Trials for duvelisib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Verastem, Inc.Phase 2
National Cancer Institute (NCI)Phase 2
OHSU Knight Cancer InstitutePhase 2

See all duvelisib clinical trials

Synonyms for duvelisib
(S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
(S)-3-(1-(7H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-
1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-
1201438-56-3
610V23S0JI
8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one
A12422
AB0032504
AC-30239
AJ-128213
AK145604
AKOS022186370
AOB87713
AS-16309
AX8268013
BC600328
BCP07042
BDBM50193013
CHEBI:131169
CHEMBL3039502
compound 4904 [Patent US8193182]
Copiktra
Copiktra (TN)
CS-0888
D10555
DB11952
DTXSID80152697
Duvelisib (IPI-145 INK1197)
Duvelisib (IPI-145, INK1197)
Duvelisib (USAN/INN)
Duvelisib [USAN:INN]
EX-A1562
GTPL7795
HY-17044
INK-1147
INK-1197
INK-1197|||IPI-145|||8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
INK1197
IPI 145
IPI-145
IPI-145 (INK1197)
IPI-145 pound>>Duvelisib
ipi-145-ink1197
IPI-145, INK 1197, Duvelisib
IPI145
KS-0000062P
MFCD15144635
NCGC00351482-01
QC-10232
s7028
SB16470
SCHEMBL153543
SCHEMBL18343557
SCHEMBL19670020
SCHEMBL20580104
SJVQHLPISAIATJ-ZDUSSCGKSA-N
ST24036081
SW219822-1
SYN1175
UNII-610V23S0JI
W-5592
X5816
ZINC88346058

US Patents and Regulatory Information for duvelisib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Moodys
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.